Annual report pursuant to Section 13 and 15(d)

Condensed Consolidated Balance Sheets

v2.4.0.8
Condensed Consolidated Balance Sheets (USD $)
In Thousands, unless otherwise specified
Dec. 31, 2013
Dec. 31, 2012
Current assets:    
Cash and cash equivalents $ 185,798 [1] $ 27,361 [1]
Accounts receivable, net 19,767 [1] 21,162 [1]
Inventory, net 18,079 [1] 22,261 [1]
Prepaid expenses and other current assets 19,084 [1] 7,873 [1]
Total current assets 242,728 [1] 78,657 [1]
Property, plant, equipment, and investment properties, net 17,027 [1] 16,526 [1]
Intangible assets, net 74,533 [1] 84,238 [1]
In-process research and development 793,341 [1] 11,546 [1]
Goodwill 226,373 [1] 80,450 [1]
Investments, net 30,653 [1] 15,636 [1]
Other assets 6,861 [1] 2,777 [1]
Total assets 1,391,516 [1] 289,830 [1]
Current liabilities:    
Accounts payable 13,414 [1] 10,200 [1]
Accrued expenses 65,874 [1] 24,656 [1]
Current portion of lines of credit and notes payable 12,562 [1] 17,526 [1]
Total current liabilities 91,850 [1] 52,382 [1]
3.00% convertible senior notes, net of discount and estimated fair value of embedded derivatives 211,912 [1] 0 [1]
Other long-term liabilities, principally contingent consideration and deferred tax liabilities 214,775 [1] 34,168 [1]
Total long-term liabilities 426,687 [1] 34,168 [1]
Total liabilities 518,537 [1] 86,550 [1]
Commitments and contingencies:    [1]    [1]
Series D Preferred Stock - $0.01 par value, 2,000,000 shares authorized; no shares issued or outstanding at December 31, 2013 and 1,129,032 shares issued and outstanding (liquidation value of $30,595) at December 31, 2012 0 [1] 24,386 [1]
Equity:    
Common Stock - $0.01 par value, 750,000,000 shares authorized; 414,818,195 and 305,560,763 shares issued at December 31, 2013 and 2012, respectively 4,148 [1] 3,056 [1]
Treasury Stock - 2,264,063 shares and 2,293,056 shares at December 31, 2013 and 2012, respectively (7,362) [1] (7,457) [1]
Additional paid-in capital 1,379,383 [1] 565,201 [1]
Accumulated other comprehensive income 3,418 [1] 7,356 [1]
Accumulated deficit (503,177) [1] (388,770) [1]
Total shareholders’ equity 876,410 [1] 179,386 [1]
Noncontrolling interests (3,431) [1] (492) [1]
Total equity 872,979 [1] 178,894 [1]
Total liabilities, Series D Preferred Stock, and equity 1,391,516 [1] 289,830 [1]
Series A Preferred Stock
   
Equity:    
Preferred Stock 0 [1] 0 [1]
Series C Preferred Stock
   
Equity:    
Preferred Stock $ 0 [1] $ 0 [1]
[1] As of December 31, 2013 and 2012, total assets include $6.7 million and $5.6 million, respectively, and total liabilities include $10.4 million and $5.5 million, respectively related to SciVac Ltd (“SciVac”), previously known as SciGen (I.L.) Ltd, a consolidated variable interest entity. SciVac’s consolidated assets are owned by SciVac and the holders of SciVac’s consolidated liabilities have no recourse against us. Refer to Note 3.